Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer

Introduction: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.Areas covered: This review will cover immunotherapies ranging for well-studied BCG administration to...